Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Noiiglutide - Jiangsu Hansoh Pharmaceutical

X
Drug Profile

Noiiglutide - Jiangsu Hansoh Pharmaceutical

Alternative Names: HS 20004; HTI-2088; Noiigliutide-injection; SHR-20004

Latest Information Update: 15 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hansoh Pharmaceutical
  • Developer Hengrui Therapeutics; Jiangsu Hansoh Pharmaceutical; Jiangsu Hengrui Medicine Co.
  • Class Antihyperglycaemics; Glucagon-like peptides; Obesity therapies; Peptides
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 26 Dec 2023 Jiangsu HengRui Medicine initiates enrolment in a phase I trial in Type 2 diabetes mellitus (In volunteers) in China (SC) (NCT06137469)
  • 17 Nov 2023 Jiangsu HengRui Medicine plans a phase I trial for Type 2 diabetes mellitus (In volunteers) in December 2023 (SC, Injection) (NCT06137469)
  • 19 Oct 2022 Phase I development is ongoing in China for Type-2-diabetes-mellitus (Jiangsu Hengrui Medicine pipeline, October 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top